Cancer immunity is mediated through the effective priming and activation of tumour-specific class I MHC molecule-restricted CD8 + cytotoxic T 
Summary
Cancer immunity is mediated through the effective priming and activation of tumour-specific class I MHC molecule-restricted CD8 + cytotoxic T lymphocytes (CTLs). DEC-205 + dendritic cells (DCs) can cross-present the epitope(s) of captured tumour antigens associated with class I MHC molecules alongside co-stimulatory molecules to prime and activate tumour-specific CD8 + CTLs. Immunosuppressive tolerogenic DCs with reduced co-stimulatory molecules may be a cause of impaired CTL induction. Hepa1-6-1 cells were established from the mouse hepatoma cell line Hepa1-6; these cells grow continuously after subcutaneous implantation into syngeneic C57BL/6 (B6) mice and do not prime CD8 + CTLs. In this study, we show that the growth of ongoing tumours was suppressed by activated CD8 + CTLs with tumour-specific cytotoxicity through the administration of the glycolipid a-galactosylceramide (a-GalCer), which is a compound known to stimulate invariant natural killer T (iNKT) cells and selectively activate DEC-205 + DCs. Moreover, we demonstrated that sequential repetitive intraperitoneal inoculation with a-GalCer every 48 hr appeared to convert tolerogenic DEC-205 + DCs into immunogenic DCs with a higher expression of co-stimulatory molecules and a stronger cross-presentation capacity, which primed CTL precursors and induced tumour-specific CD8 + CTLs within the tumour environment without activating iNKT cells. These findings provide a new basis for cancer immunotherapy to convert tolerogenic DEC-205 + DCs within tumours
Introduction
The most effective cells for eliminating tumour cells are CD8 + cytotoxic T lymphocytes (CTLs) that specifically recognize the tumour antigens presented in association with class I MHC molecules. 1 To prime and activate CTLs in a tumour environment, dendritic cells (DCs) are key cells that uptake tumour proteins, process them into peptide fragments containing immunodominant epitope (s), and present them on their surface associated with antigen-presenting class I MHC molecule(s) for the activation of specific T-cell immunity. 2, 3 In general, externally captured antigenic molecules are fragmented into small peptide pieces within the endosome and are presented in conjunction with class II MHC molecules, which prime CD4 + helper T cells, whereas internally synthesized proteins are broken into tiny fragments containing epitope peptides and are presented with class I MHCs, which prime CD8 + CTLs. 4, 5 Recently, a unique DC subtype expressing the molecule DEC-205 was shown to have the capacity to present an epitope of an externally captured antigenic protein in association with class I MHCs, which was called 'crosspresentation', [6] [7] [8] [9] and the cross-presented antigenic epitope was specifically recognized by CD8 + CTLs for both mice and humans. Moreover, the priming and activation of antigen-specific CD8 + CTLs required co-stimulatory signalling via CD80 and CD86. 10 Hence, CD8 + CTLs, which are tumour-specific, can be primed and activated by tumour-antigen-loaded activated + DCs expressing co-stimulatory molecules. 11, 12 We have established two distinct types of murine hepatoma cell lines, called Hepa1-6-1 and Hepa1-6-2, from known Hepa1-6 cells 13 and confirmed that they displayed similar antigenicity as well as an identical surface expression of class I MHC. 11, 13 After subcutaneous (s.c.) implantation into syngeneic C57BL/6 (B6) mice, Hepa1-6-1 cells showed continuous growth and did not prime CD8 + CTLs, whereas Hepa1-6-2 cells failed to grow in vivo and efficiently primed the CTLs. 11 Through a careful examination of the cells within these two distinct tumours, among tumour-infiltrating DCs (TIDCs), we found that the DEC-205 + tolerogenic DCs had reduced levels of co-stimulatory molecules as well as impaired cross-presenting capacities in the Hepa1-6-1-derived tumour mass but not within the Hepa1-6-2-derived tumour mass, and we concluded that the tolerogenic DCs may be a cause of the impaired CTL induction. 11 Based on these findings, we questioned whether we could alter the conditions of the DEC-205 + tolerogenic DCs within the Hepa1-6-1-derived tumour into immunogenic DCs with higher expression levels of co-stimulatory molecules using the external administration of a-galactosylceramide (a-GalCer), a potent activator of DEC-205 + DCs. 14 In this study, we show for the first time that the growth of an ongoing Hepa1-6-1-derived tumour mass was profoundly suppressed by internally induced Hepa1-6-1-specific CD8 + CTLs but not by the activated invariant natural killer T (iNKT) cells through a sequential repetitive intraperitoneal (i.p.) inoculation with a-GalCer every other day. With these findings, a new notion can be proposed for cancer immunotherapy using the selective activation of immunosuppressive tolerogenic DCs within tumours by sequential administration with a known glycolipid antigen, such as a-GalCer.
Materials and methods

Mice
Seven-week-old female B6 (H-2 b ) mice were purchased from Charles River Japan (Kanagawa, Japan), maintained in microisolator cages under pathogen-free conditions, and fed autoclaved laboratory chow and water. The iNKT cell knockout (Ja18 KO) mice on the B6 background were a kind gift from M. Taniguchi (RIKEN Institute, Yokohama City, Japan). 15 All animal experiments were performed according to the Guidelines for the Care and Use of Laboratory Animals set by the National Institutes of Health (NIH; Bethesda, MD) and were approved by the Review Board of Nippon Medical School (Tokyo, Japan).
Culture medium
The medium used for culturing immunocompetent cells, such as CTLs, was an RPMI-1640 (Sigma-Aldrich, St Louis, MO) -based complete culture medium 16 supplemented with 50 mM 2-mercaptoethanol (Invitrogen Life Technologies, Carlsbad, CA), 2 mM L-glutamine (SigmaAldrich), 1 mM sodium pyruvate (Invitrogen), 0Á1 mM non-essential amino acids (Invitrogen), a mixture of vitamins (Invitrogen), 1 mM HEPES (Invitrogen), 100 U/ml penicillin (Invitrogen), 100 lg/ml streptomycin (Invitrogen), and 10% heated fetal calf serum (FCS; HyClone, Logan, UT). Some of the tumour cells were cultured in either Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 1 mM HEPES, 100 U/ml penicillin (Invitrogen), 100 lg/ml streptomycin and 10% heated FCS (D-10) or with RPMI-1640 supplemented with 1 mM HEPES, 100 U/ml penicillin, 100 lg/ml streptomycin and 10% heated FCS (R-10).
Establishment of Hepa1-6-1 and Hepa1-6-2 cell lines
The murine hepatoma cell line, Hepa1-6, which was established from B6 (H-2 b ) mice, was purchased from the American Type Culture Collection (ATCC, Rockville, MD). The murine hepatoma cell lines Hepa1-6-1 and Hepa1-6-2 were established from Hepa1-6. 11 Briefly, Hepa1-6-1 cells were obtained from the purified cells of a collagenase-digested and surgically removed tumour mass that was grown for approximately 3 months after the s.c. implantation of Hepa1-6 cells into syngeneic B6 mice and were maintained in D-10 medium. Hepa1-6-2 is a controllable tumour line that demonstrates spontaneous regression obtained by the repetitive in vitro transfer of Hepa1-6 cells for several months in R-10 medium. 
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Tumour injections and measurement of tumour size Ten million tumour cells with 100 ll of RPMI-1640 were s.c. injected into the abdominal region of each mouse with a 27-gauge needle syringe. For estimating the volume of the growing tumour mass, the diameters for both the length (a) and the width (b) were measured every day until day 24 after implantation, and the tumour volume (V) was calculated according to the formula V = ab 2 /2 as previously described. 11 When the longer axis of each tumour was > 20 mm in diameter, the mice were anaesthetized and killed according to the NIH guidelines.
In vivo activation of DEC-205 + DCs
The in vivo activation of the DEC-205 + DCs was performed by the injection of a-GalCer (KRN7000; Funakoshi Co., Ltd., Tokyo, Japan). 17, 18 To dissolve KRN7000, we used 0Á025% Polysolvate-20 in PBS to dissolve the material according to the manufacturer's instructions. The mice were given an i.p. injection of 2 lg a-GalCer in 100 ll of 0Á025% Polysolvate-20 in PBS every other day from day 0 to day 18.
In vivo depletion of CD8 + T cells, CD4 + T cells and NK cells
For in vivo deletion of CD8 + T cells or CD4 + T cells, mice were given two i.p. injections (on days 1 and 3) of 400 lg/mouse anti-Lyt2 (3.155; ATCC) or 400 lg/mouse anti-mouse CD4 (GK1.5; BioLegend, San Diego, CA). For the deletion of NK cells, mice were intravenously (i.v.) injected twice (on days 1 and 3) with 50 ll/mouse antiasialo-GM1 (poly21460; BioLegend). Flow cytometry analysis confirmed that > 95% of the CD8 + T cells, CD4 + T cells and NK cells in the spleen had been depleted.
Interleukin-12 administration to Hepa1-6-1-implanted mice
For the interleukin-12 (IL-12) administration into Hepa1-6-1-implanted mice, 100 ng/mouse IL-12p70 (R&D Figure S1 ).
Tumour-infiltrating lymphocyte isolation
For isolation of the tumour-infiltrating lymphocytes, the tumours were excised from the mice and digested with 1 mg/ml collagenase (Roche Diagnostics GmbH, Mannheim, Germany) for 45 min at 37°. Then, the tissue was crushed gently to homogenize it and filtered through a nylon mesh. To obtain purified tumour-infiltrating lymphocytes (TILs), the isolated leucocytes were further purified from other haematopoietic cells with a mouse CD8 + T-cell isolation cocktail containing a combination of biotinylated monoclonal antibodies (mAbs) directed against the cell surface antigens CD4, CD11b, CD11c, CD19, CD24, CD45R/B220, CD49b, T-cell receptor-c/d and TER119 as well as nanoparticles. The cells were negatively sorted with the immunomagnetic system (StemCell Technologies, Vancouver, BC, Canada), which yielded a population containing approximately 95% purified CD8 + TILs.
Purification of CD11c + TIDCs
To purify the tumour-infiltrating CD11c + cells, the TIL suspension was incubated with PE-labelled anti-CD11c followed by a PE-selection cocktail and nanoparticles and was positively sorted with the immunomagnetic system (StemCell Technologies), which yielded a population containing approximately 95% purified CD11c + TIDCs.
Induction of bone marrow-derived DCs
Bone marrow (BM) cells prepared from femurs and tibias of syngeneic B6 mice were depleted of red blood cells using osmotic haemolysis, as recently described. 19 Next, 1 9 10 6 BM cells were plated on 24-well culture plates and incubated in complete culture medium supplemented with 20 ng/ml of murine recombinant granulocyte- 2 µg ever other day administration *** *** macrophage colony-stimulating factor (Peprotech, Rockey Hill, NJ). On day 2 of culture, the floating cells were gently removed, and fresh medium was co-cultured with 1 9 10 5 Hepa1-6-1 cells in the trans-well system (Corning, Kennebunk, ME). On day 5, non-adherent cells were collected and analysed using flow cytometry.
Re-stimulation of Hepa1-6-2-specific primed lymphocytes with CD11c + TIDCs or BM-derived DCs
One million Hepa1-6-2 cells in 200 ll of PBS were i.p. injected into each B6 mouse with a 27-gauge needle syringe. Approximately 14 days after the Hepa1-6-2 inoculation, an additional administration of 1 9 10 6 of the original Hepa1-6-2 cells was performed. One week after the Hepa1-6-2 inoculation, 1 9 10 5 primed splenic CD8 + T cells were obtained by positively sorting with the immunomagnetic system (StemCell Technologies), which yielded a population containing approximately 95% purified CD8 + T cells, labelled with 5 mM carboxyfluorescein diacetate succinimidyl ester (CFSE) and further co-cultured with either 5 9 10 4 CD11c + TIDCs or BM-derived DCs pulsed with hepa1-6-1 lysate obtained from 5 9 10 3 Hepa1-6-1 cells overnight and completely washed out to remove free antigen in a 200 ll round-bottom 96-well cell culture plate for 4 days. Next, the re-stimulated cells were harvested and analysed using flow cytometry to determine the number of cell divisions, which correlated with the ability of the TIDCs to prime T cells.
In vitro induction of Hepa1-6-1-specific CTLs Four million spleen cells obtained from sequentially a-GalCer-treated Hepa1-6-1-implanted mice were re-stimulated with 1 9 10 5 /well Hepa1-6-1 cells treated with mitomycin-C (Kyowa Hakko-Kirin, Tokyo, Japan) for 5 days in 24-well culture plates with 1Á0 ml of complete culture medium containing 10% rat concanavalin A supernatantcontaining medium (Rat T-STIM; Corning, Bedford, MA).
CTL assay
A standard chromium-51-release assay was performed to determine the cytotoxicity of the purified CD8 + TILs, or generated Hepa1-6-specific immune cells, as previously described. 16 Briefly, various numbers of effector cells were incubated with 5 9 10 3 chromium-51-labelled targets for 4 hr at 37°in 200 ll of RPMI-1640 containing 10% warmed FCS in a round-bottom 96-well cell culture plate. After incubation, the plate was centrifuged for 10 min at 330 g, and 100 ll of the cell-free supernatant was collected to measure the radioactivity with a Packard AutoGamma 5650 counter (Hewlett-Packard, Tokyo, Japan). The maximum release was determined from the supernatant of the cells that had been lysed by the addition of 5% Triton X-100, and the spontaneous release was determined from the target cells incubated without the added effector cells. The percentage of specific lysis was calculated as 100 9 (experimental release -spontaneous release)/ (maximum release -spontaneous release).
Priming of CD8 + CTLs from naive T cells by a-GalCeractivated DCs
To examine the effect of a-GalCer-activated DCs on CTL priming, TIDCs from Hepa1-6-1-implanted B6 mice with an i.p. injection of 2 lg/mouse a-GalCer every other day for 14 days were co-cultured with syngeneic splenic naive T cells obtained by passing them through a nylon wool column as previously described. 20 TIDCs (1 9 10 5 /well) and purified naive splenic T cells (5 9 10 5 /well) were cocultured in a flat-bottom 96-well cell-culture plate. After 4 days of culture, cells were collected and the percentages of naive T cells (CD3 + CD8 + CD44 À CD62L + ) and memory T cells (CD3 + CD8 + CD44 + CD62L À ) were evaluated by flow cytometry. After a week, the primed T cells were further incubated with mitomycin-C-treated Hepa1-6-1 cells for 48 hr and the amount of interferon-c secreted in the culture supernatant was measured by ELISA. 
Statistical analysis
The results were analysed using a Student's t-test, and the results are presented as the mean AE SEM. Differences at P < 0Á05 were considered significant. The statistical analysis was performed using PRISM software (GraphPad Software, La Jolla, CA).
Results
Effect of the administration of Hepa1-6-1-specific CD8 + CTLs on Hepa1-6-1 tumour growth in vivo
We previously reported that we have established two distinct types of murine hepatoma cell lines, Hepa1-6-1 and Hepa1-6-2, 11 from the known hepatoma cell line Hepa1-6. 13 We confirmed that these cells showed similar antigenicity as well as identical surface class I MHC molecule restriction. 21 The original Hepa1-6-1 cells showed continuous growth after s.c. implantation into syngeneic B6 mice and did not prime CD8 + CTLs, whereas the Hepa1-6-2 cells failed to grow in vivo by Hepa1-6-2-specific CD8 + CTLs, which also efficiently eliminated Hepa1-6-1 cells in vitro.
11 Therefore, we first established Hepa1-6-2-specific CD8 + CTLs through the repetitive stimulation of Hepa1-6-2-primed spleen cells with Hepa1-6-2 tumour cells in vitro and confirmed that these cells specifically killed both Hepa1-6-1 and Hepa1-6-2 cells in vitro (Fig. 1a) . In addition, we confirmed that there was no difference in H-2D b class-I MHC molecule expression between Hepa1-6-1 and Hepa1-6-2 cells (Fig. 1b) . These results clearly indicated that both the Hepa1-6-1 and Hepa1-6-2 tumour cell lines express the same epitopes and the same levels of MHC class I molecules. Then, we applied 1 9 10 6 of the Hepa1-6-2-specific CD8 + CTLs s.c. into the tumour mass of B6 mice that were implanted with Hepa1-6-1 cells 7 days before the CTL administration, when the implanted Hepa1-6-1 cells had established a solid tumour mass. 11 However, the growth of the implanted Hepa1-6-1 cells was not inhibited at all (Fig. 1c) . We also examined the effects of the i.v. administration of 1 9 10 6 Hepa1-6-2-specific CD8 + CTLs/ mouse to the mice implanted with Hepa1-6-1 cells. Similar to the findings obtained by i.v. administration of 1 9 10 6 OVA-specific CD8 + CTLs/mouse 21 the growth of the tumour was not at all inhibited (Fig. 1d) . These findings indicate that adoptive immunotherapy using tumour-specific CTLs does not work in this system.
Activation of DEC-205 + DCs in vivo by i.p. injection of a-GalCer in B6 mice
We recently reported that CD11c + DEC-205 + DCs are selectively activated in vivo through the i.p. injection of a-GalCer in BALB/c mice.
14 Based on this finding, we examined whether a-GalCer also selectively stimulated DEC-205 + DCs in the spleen cells of B6 mice. We prepared spleen cells from B6 mice at 6, 12, 24 and 48 hr after the i.p. injection of a-GalCer at 2 lg/mouse and analysed the kinetics in terms of the percentage and the number of DEC-205 + or 33D1 + cells among the CD11c + DCs using flow cytometry and a haemocytometer. We found that among the CD11c + DC subsets, the percentage ( Fig. 2a; left panel) as well as the actual number ( Fig. 2a ; right panel) of DEC-205 + DCs significantly increased to their peak value at approximately 12 hr after injection, whereas the percentage ( Fig. 2a ; left panel) and number ( Fig. 2a; right À DCs was up-regulated and reached an optimal value at approximately 24 hr before the expression began to decline 48 hr after stimulation with a-GalCer (Fig. 2b) . Moreover, IL-12 production in the sera similarly increased and reached its maximum at approximately 6 hr and then declined 48 hr after the administration of 2 lg/mouse a-GalCer (Fig. 2c) . These data suggest that We further examined the effect of boosting expression with a-GalCer on the percentage of DEC-205 + DCs in aGalCer-immunized B6 mice. When the immunized mice were boosted with a-GalCer 48 hr after the initial i.p. injection, the percentage of DEC-205 + DCs similarly increased from 20% to 50% and reached its maximum at approximately 12 hr before it rapidly declined ( Fig. 2d ; open inverse triangle). However, the percentage of DEC-205 + DCs in the primed mice showed a weak response at approximately 6 hr when it was boosted with a-GalCer at both 24 and 48 hr ( Fig. 2d; closed triangle) . These data suggest that innate immunity, especially DEC-205 + DCs, can be activated by stimulation at a 48-hr, but not a 24-hr, interval to achieve the maximum response with lipid/glycolipid a-GalCer.
Next, we investigated the expression of the CD1d molecule and the a-GalCer-CD1d complex on DEC-205 + DCs as well as 33D1 + DCs by using a unique mAb (L363) that responds predominantly to the a-GalCer-CD1d complex. The CD1d expression on DEC-205 + DCs was far higher than that on 33D1 + DCs (Fig. 2e) . To our surprise, the a-GalCer-CD1d complex was predominantly observed on DEC-205 + DCs (Fig. 2f) . Therefore, the DEC-205 + DCs seem to be selectively activated by a-GalCer through the CD1d molecules on them.
Effects of the selective activation of TIDCs within the Hepa1-6-1 tumour mass on tumour growth by the external administration of a-GalCer
We then investigated whether the activation of tolerogenic TIDCs within the Hepa1-6-1 tumour mass could suppress tumour growth in vivo through a single administration of high-dose a-GalCer. Hepa1-6-1 cells (1 9 10 7 ) were implanted s.c. into the right abdominal region of syngeneic B6 mice, and 2 hr later (day 0), the tumour-implanted mice were treated i.p. once with either 20 lg a-GalCer or 0Á025% Polysolvate-20 in 100 ll of PBS as a vehicle control. The growth kinetics of the Hepa1-6-1 tumour volume was evaluated by measuring the diameter of the length and the width daily until day 24 after the implantation. The Hepa1-6-1-implanted control mice, which were given 0Á025% Polysolvate-20 in 100 ll of PBS alone, established a solid tumour mass after approximately 7 days, whereas the tumour growth in mice that received 20 lg a-GalCer was weakly suppressed, despite the high dose of a-GalCer (Fig. 3a) .
As indicated in Fig. 2(a-f) , we confirmed that innate DEC-205 + DCs could be selectively activated in a 48-hr rather than a 24-hr cycle stimulation with 2 lg of a-GalCer in vivo. Based on these findings, we attempted to determine the effect of 10 sequential injections of a-GalCer at 2 lg/ mouse at 48-hr intervals beginning 2 hr after the Hepa1-6-1 implantation until day 18. We compared the results with those of Hepa1-6-1-implanted mice that were injected with 20 lg/mouse a-GalCer once. Although the total amount of a-GalCer was the same, the effect of the sequential repetitive activation of the DEC-205 + DCs with 2 lg/mouse of a-GalCer every other day was potent (Fig 3b,c) . To confirm the findings, we plotted the volume of each tumour for 24 days after implantation and confirmed the stability of the suppressive effect (Fig. 3d) . These results indicate that sequential administration with a smaller amount of a-GalCer every other day induced a more stable and potent suppressive effect on tumour growth.
Moreover, we examined the effect of depletion of either CD8 + T cells, CD4 + T cells, or NK cells on tumour growth in the sequentially a-GalCer-administered Hepa1-6-1 tumour-implanted mice. As demonstrated in Fig. 3(e) , the inhibitory effect of tumour growth by aGalCer-administration was apparently abolished by CD8 + T-cell depletion but not by CD4 + T-cell or NK cell depletion. Therefore, the inhibitory effect of a-GalCer-administration requires CD8 + T cells but not CD4 + T cells or NK cells. Additionally, the effect of sequential i.p. administration of 100 ng/mouse IL-12p70 into tumour-implanted mice was examined and found that the tumour growth was moderately inhibited. Indeed, we detected approximately 3000 pg/ml of IL-12 in the blood of a-GalCeradministered tumour-growth-suppressed mice (Fig. 3f) and concluded that the very small amount of IL-12 secreted in vivo appeared to inhibit tumour growth.
Effects of sequential i.p. administration of a-GalCer into tumour-bearing mice every other day on the activation of CD8 + TILs and TIDCs
Next, we examined the characteristics of the TILs in the Hepa1-6-1 tumour mass in the a-GalCer-administered B6 mouse to determine whether the Hepa1-6-1-specific 
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CD8 + CTLs were primed and activated. We examined the expression of an activation marker, CD69, on the TILs using flow cytometry 7, 10 and 14 days after Hepa1-6-1 implantation in both a-GalCer-administered and control vehicle-injected B6 mice. The CD3 + TILs in the a-GalCeradministered B6 mice were significantly activated with enhanced CD69 expression ( Fig. 4a ; panels in the first lane). In particular, the percentage of CD8 + TILs significantly increased by a-GalCer administration ( Fig. 4a ; panels in the second lane). Moreover, CD8 + T cells bearing enhanced CD69 expression in the TILs were also strongly activated ( Fig. 4a ; panels in the third lane). Conversely, the CD69 expression on NK1.1 + NK cells in the TILs was almost unchanged by the a-GalCer injection ( Fig. 4a ; panels in the fourth lane). These findings suggest that ongoing tumour growth can be suppressed by activated CD8 + CTLs with tumour-specific cytotoxicity through sequential i.p. administration of a-GalCer every other day.
We then confirmed that the selective activation of DEC-205 + DCs in vivo could be achieved by an i.p. injection of a-GalCer in B6 mice (Fig. 2b) . Hence, we examined the phenotype and expression of co-stimulatory molecules on the TIDCs in the sequentially a-GalCeradministered B6 mice 10 days after Hepa1-6-1 implantation by flow cytometry. Enhanced expression of CD80 and CD86 on the CD11c + class II + DEC-205 + TIDCs in the a-GalCer-treated mice (Fig. 4b) but not in the CD11c + 33D1 + TIDCs was apparently observed (Fig. 4c) . These findings suggest the possibility that sequential i.p. administration of a-GalCer prevents the induction of tolerogenic DEC-205 + DCs or converts them into immunogenic DCs expressing higher amounts of CD80/ 86 that may specifically prime CTL precursors.
Comparison of the number of iNKT cells between aGalCer-treated mice and untreated mice a-GalCer is also known as a compound that specifically stimulates iNKT cells via CD1d on the DEC-205 + DCs. To confirm whether the iNKT cells were actually activated within the TILs, the number and activation of iNKT cells in the spleen, as well as in the TILs, of the Hepa1-6-1-implanted mice treated repetitively with a-GalCer, were examined 10 days after tumour implantation. Compared with that in the mice not administered a-GalCer, no significant differences in the number of a-GalCer-specific CD1d-restricted iNKT cells (Fig. 5a ) and CD69 + -activated iNKT cells (Fig. 5b) were observed. Moreover, we examined whether the a-GalCer treatment could suppress growth of tumoir in iNKT KO mice. As demonstrated in Fig. 5(c) , tumour growth was also markedly inhibited in iNKT-deficient Ja18 -/-(Ja18 KO) mice 19 with sequential i.p. administration of 2 lg/mouse a-GalCer every other day, indicating that the a-GalCer-activated CD8 + T cells but not iNKT cells may be the actual effector cells for the anti-tumour reaction iNKT KO mice. These findings suggest that the major effectors for suppressing Hepa1-6-1 growth were not the activated iNKT cells but rather the activated tumour-specific CD8 + CTLs in the tumourbearing mice treated with a-GalCer.
Sequential administration of a-GalCer in vivo appears to induce priming and activation of Hepa1-6-1-specific CD8 + CTLs
As indicated above, the sequential administration of a-GalCer every 48 hr in vivo appeared to convert tolerogenic DEC-205 + DCs into immunogenic DCs that will prime tumour-specific CTL precursors, which may be activated by neighbouring immunogenic DCs that express higher amounts of CD80/86 within the Hepa-1-6-1 tumour mass. To examine this possibility, we performed a standard chromium-51-release assay to determine whether cytotoxicity of the primed CD8 + CTLs within the spleen of the a-GalCer-treated Hepa-1-6-1-bearing mice was observed. We observed specific cytotoxicity against Hepa1-6-1 tumour cells when the primed spleen cells were re-stimulated in vitro with Hepa1-6-1 cells in the Hepa1-6-1-implanted B6 mice treated with repetitive a-GalCer but not in the untreated mice (Fig. 6a) . The cytotoxicity may be initiated through the cross-presenting capacity of the converted immunogenic DEC-205 + DCs that presented captured tumour antigen(s) in association with class I MHC molecules and co-stimulation molecules for priming virgin splenic T cells.
To confirm this possibility, we examined the cross-presenting capacity of the DEC-205 + TIDCs in the Hepa-1-6-1-bearing mice that were repetitively treated with 2 lg/ mouse a-GalCer every other day until day 18. The CD11c + TIDCs were enriched from a Hepa1-6-1 tumour mass using a magnetic separation kit and were co-cultured with CFSE-labelled primed splenic T cells from mice pre-immunized i.p. with Hepa1-6-2 cells 4 days previously. Then, the co-cultured cells were harvested and analysed by flow cytometry. The Hepa1-6-2-primed splenic T cells were apparently activated when the cells were stimulated with the TIDCs from the a-GalCer-treated mice implanted with Hepa1-6-1. In contrast, the primed T cells were not significantly activated when the cells were stimulated with the control TIDCs from mice treated with vehicle alone (Fig. 6b) . Hence, we confirmed that the TIDCs from the Hepa1-6-1 tumour-bearing mice that were repetitively treated with a-GalCer gained the ability to specifically activate primed splenic T cells. These findings suggest that the tolerogenic TIDCs within the Hepa1-6-1 tumour mass might be converted into immunogenic DCs, which had the ability to prime virgin T cells.
We showed here that a-GalCer initiated the internal activation of tolerogenic DCs within the tumours and the activated tolerogenic DCs gained a suppressive ability against tumour growth through priming and activation of tumour-specific CD8 + CTLs. Therefore, we examined whether the TILs within the tumour mass showed Hepa1-6-1 tumour cell-specific cytotoxicity ex vivo when a-GalCer was sequentially administered to the mice. The specific cytotoxicity against the Hepa1-6-1 tumour cells was detected in the TILs. However, the TILs in the vehicle-treated control mice bearing Hepa1-6-1 showed no cytotoxicity (Fig. 6c) . These findings suggest that the sequential administration of a-GalCer to the Hepa1-6-1-bearing mice induced tumour-specific CD8 + CTLs within the tumour mass through converting tolerogenic DEC-205 + TIDCs into immunogenic DCs that gained the ability to cross-present and had augmented costimulatory molecules.
Effects of a-GalCer on converting tolerogenic DEC-205 + DCs induced by Hepa1-6-1 tumour cells into immunogenic DCs in vitro Finally, we wished to determine whether tolerogenic DEC-205 + DCs expressing down-regulated co-stimulation molecules could be converted into immunogenic cells by treating them with a-GalCer. BM-derived DCs were incubated with Hepa-1-6-1 cells in the trans-well system, which is a system in which the DCs can only be reached by humoral factors secreted from Hepa-1-6-1 tumours. When the DCs were incubated in the culture supernatant of Hepa1-6-1 cells for 5 days, the expression of CD86 costimulatory molecules on the DEC-205 + DCs was markedly down-regulated, indicating that the cells became tolerogenic (Fig. 7a) . However, when the tolerated DCs were treated with 100 ng/ml of a-GalCer in the presence of Hepa1-6-1 cells using a trans-well system for an additional 24 hr, CD86 expression on the DEC-205 + DCs was almost completely recovered to a normal or slightly enhanced level (Fig. 7b) . Moreover, these recovered DCs treated with a-GalCer gained the ability to stimulate Hepa1-6-2-primed splenic T cells (Fig. 7c) . Furthermore, we examined whether a-GalCer treatment could induce priming of naive T cells. Here, we found that, when splenic naive T cells from normal B6 mice were co-cultured with TIDCs from Hepa1-6-1-bearing mice given i.p. injections of 2 lg/mouse a-GalCer every other day for 14 days, the CD44 À CD62L + naive T cells were converted into the CD44 + CD62L À memory T cells (Fig. 7d ) and the converted memory T cells secreted interferon-c when stimulated with Hepa1-6-1 cells for a further 48 hr (Fig. 7e) . Collectively, sequential administration of a-GalCer into the tumour-implanted mice not only converted the tolerogenic DCs into immunogenic cells but also induced the priming of naive T cells into tumour-specific CD8 + CTLs together with providing DCs with the crosspresenting ability of captured tumour antigens.
Discussion
In the present study, we showed that sequential repetitive i.p. administration of a-GalCer every 48 hr in hepatomacell-bearing mice initiated tumour-specific CD8 + CTLs among the TILs in vivo. a-GalCer is a glycolipid associated with CD1d molecules that can activate iNKT cells. 17, 18 Indeed, in cases of human myeloma or glioma cells, a-GalCer-activated iNKT cells recognize endogenous glycolipids in these tumour cells and eliminate them. anti-tumour response. 23 However, as shown in this study, the number of CD69 + -activated iNKT cells was not increased in mice that were repeatedly treated with a-GalCer (Fig. 5a ). This outcome may have occurred because the frequent stimulation of innate iNKT cells with a-GalCer drives them into anergy rather than activation. Indeed, it was reported that sequential administration of a-GalCer resulted in iNKT cells that were unresponsive and drove them into an anergic state. 24 Therefore, the suppressive effect of sequential administration with a-GalCer on Hepa1-6-1 tumour growth was not correlated with iNKT cells but rather with other immune effectors activated by a-GalCer. In addition, as demonstrated here, sequential administration with a-GalCer inhibited Hepa1-6-1 tumour growth in vivo even in the iNKT-deficient mice. Additionally, in vivo suppression of Hepa1-6-1 growth appears to be mediated by CD8 + CTLs. Moreover, It should be noted that only a small amount of IL-12 (approximately 3000 pg/ml) was detected in the sera of a-GalCer-administered tumourregressed mice, indicating that a small amount of IL-12 seems to be sufficient in the DEC-205 + DC-activated state for tumour-growth suppression.
In the tumour microenvironment, cancer cells secrete a variety of immunosuppressive factors. As we previously reported, Hepa1-6-1 cells secrete various humoral factors, such as a-fetoprotein, transforming growth factor-b and vascular endothelial growth factor, which down-regulate the co-stimulatory molecules on DCs. Hence, the TIDCs near Hepa1-6-1 cells might become immunosuppressive tolerogenic DCs with downregulated co-stimulatory molecules. We speculated whether those tolerogenic TIDCs within the Hepa1-6-1 tumour mass might be able to cancel the effect of externally administered CD8 + CTLs that have the capacity to specifically eliminate Hepa1-6-1 cells. We confirmed that the cytotoxicity of CTLs and the effect of TIDC2 were completely abrogated. Taking all of the data into consideration, we hypothesized that the internal activation of immunosuppressive tolerogenic DCs within the tumours would inhibit tumour growth.
In our previous study, we speculated that tolerogenic DCs within the tumour mass could be converted into functional immunogenic DCs through the activation of DEC-205 + DCs. 11 Additionally, as we recently demonstrated, the selective activation of the DEC-205 + DC subset might activate tumour-specific CD8 + CTLs without additional tumour-antigen stimulation in vivo. 19, 25 In this study, we demonstrate for the first time that the sequential administration of a-GalCer every 48 hr might convert tolerogenic DCs within the tumour mass into immunogenic DEC-205 + DCs, which have an enhanced expression of co-stimulation molecules and a cross-presenting capacity that might prime and activate naive T cells within the tumour mass.
The findings presented here may provide a new basis for cancer immunotherapy to convert immunosuppressive tolerogenic DCs within tumours into immunogenic DCs through sequential external administration of an immunopotent lipid/glycolipid, such as a-GalCer, and activated immunogenic DCs with sufficient expression of co-stimulatory molecules can then prime and activate tumour-specific CD8 + CTLs within the tumour mass to control tumour growth.
